Zecs your confused and posting up trolling information again and missing half the announcement. Last time on the cholesterol drug it was preliminary readouts. The reason why the company is announcing each GLP study separately this time. The company learning from their mistakes and these announcements are not preliminary readouts but final results. The failed toxicology test was the invitro micronucleus toxicology study which we already passed last week Monday. Once the remaining two GLP final results are completed this week coming or the following, then there is no wait period it’s straight into first in human trials. The company making announcement on being far superior than first line FDA drugs in a 4 billion dollar market has already put this company on success. Not worth a 18 million market cap and the rerate will continue as safety is ticked off and the company develops it partnership from the Walter Reed results due straight after first human trials
NYR Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)